Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FAS
REST API REST API
Homo sapiens
FAS is differentially expressed in 375 experiments: 166 organism parts: lung, kidney, ... (164 more);, 231 disease states: normal, prostate carcinoma, ... (229 more);, 112 cell types 531 cell lines 63 compound treatments and 76 other conditions.
Synonyms APT1, APO-1, FAS1, CD95, TNFRSF6
Orthologs TNR6_BOVIN (Bos taurus)   ENSMUSG00000024778 (Mus musculus)   fas (Danio rerio)   FAS (Gallus gallus)   Fas (Rattus norvegicus)   NP_001096199.1 (Xenopus laevis)   FAS (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, apoptosis, regulation of cell proliferation, response to toxin, membrane, protein homooligomerization, negative regulation of apoptosis, kinase binding, spermatogenesis, activation of caspase activity, extracellular region, membrane raft, protein complex assembly, anti-apoptosis, response to hypoxia, positive regulation of apoptosis, signal transducer activity, external side of plasma membrane, soluble fraction, identical protein binding, induction of apoptosis, response to lipopolysaccharide, tumor necrosis factor receptor activity, aging, receptor activity, immune response, response to drug, perinuclear region of cytoplasm, integral to membrane, binding, cell surface, signal transduction, neuron apoptosis, regulation of apoptosis, response to cytokine stimulus, tumor necrosis factor-mediated signaling pathway, activation of pro-apoptotic gene products, inflammatory cell apoptosis, regulation of myeloid cell differentiation, activation-induced cell death of T cells, cellular response to mechanical stimulus, negative thymic T cell selection, induction of apoptosis via death domain receptors, dendrite regeneration, B cell mediated immunity, death-inducing signaling complex, gene expression, immunoglobulin production, response to estrogen stimulus, spleen development, cellular response to lithium ion, positive regulation of necrotic cell death, response to growth factor stimulus, response to inorganic substance, regulation of lymphocyte differentiation, response to peptide hormone stimulus, T cell homeostasis, induction of apoptosis by extracellular signals, transformed cell apoptosis, negative regulation of B cell activation, renal system process, ovulation cycle, response to glucocorticoid stimulus, CD95 death-inducing signaling complex, positive regulation of protein homooligomerization, transmembrane signaling receptor activity
InterPro Term TNFR_Cys_rich_reg, Death, Fas_rcpt
UniProt Accession B6VNV5, P25445, Q5T9P3, Q8IUB7, F5GWX3, F5H078
Gene-Disease Assocation AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS
Search EB-eye ENSG00000026103
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (53 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
H1437
2
E-GEOD-16194, E-MTAB-62
BT-474
2
E-GEOD-5823, E-GEOD-3529
HepG2
2
E-MTAB-37, E-GEOD-7307
525 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (51 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
mesenchymal stem cell
2
E-GEOD-2248, E-GEOD-9894
1
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
106 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (76 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MEXP-2034, E-GEOD-7307, E-MTAB-62, E-GEOD-96, E-MEXP-1327 ... (5 experiments)
dermatomyositis
3
E-GEOD-5370, E-GEOD-1551, E-MTAB-62
Huntington's disease
3
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
colon carcinoma
3
E-MTAB-62, E-MTAB-57, E-MTAB-37
gastric carcinoma
2
E-GEOD-2685, E-GEOD-15460
embryonal rhabdomyosarcoma
2
E-MEXP-121, E-MTAB-62
225 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5542, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (35 experiments)

Factor Value U/D Experiments
none
6
9
E-GEOD-5824, E-MEXP-1958, E-MEXP-1230, E-GEOD-1740, E-GEOD-5542, ... (15 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
ethanol
2
E-MEXP-2241, E-GEOD-3113
interferon-gamma
1
2
E-GEOD-1925, E-GEOD-1432, E-GEOD-5542
sapphyrin PCI-2054
1
E-GEOD-6400
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
57 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-GEOD-4667, E-MEXP-2283, E-MEXP-958, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-2509, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-GEOD-7011, E-MTAB-73, E-GEOD-4025, E-GEOD-7578, ... (11 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-TABM-868, E-GEOD-20115, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-MEXP-1273, E-TABM-263, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-923 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Processing time: 0.387 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM